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Summary
Essential thrombocythemia (ET) is one of the three non-Philadelphia-chromosome myelo-
proliferative neoplasms (MPN). It is considered to be of relatively benign clinical course with 
expected overall survival for patients approaching the one of general population. However, as 
a clonal disease of hematopoietic stem it can progress to myelofibrosis or transform into leuke-
mia. It shows increased risk of hemorrhage (when platelet counts over 1 mil/ul), or propensity 
for thrombosis. In the last 10 years tremendous advances in detecting molecular genetic defects 
responsible for MPN, including ET were made. The most important are acquired valine to phe-
nylalanine substitution at aminoacid 617 of the JAK2 (Janus Kinase 2) protein (JAK2V617F) that 
leads to constitutive activation of the tyrosine kinase, increased kinase activity and hyper-res-
ponsiveness to cytokine signaling and cell proliferation. This mutation is present in 60% of ET, 
>97% of PV and in around 50% of patients with PMF. The thrombopoietin receptor (c-MPL) is 
another oncogene in ET with W515L mutation that induces constitutive, cytokine-independent 
activation of the JAK-STAT pathway. MPLW515L or MPLW515K mutations are present in patients 
with PMF or ET at a frequency of approximately 8% and 3%, respectively, not found in PV. The 
recent important genetic discovery is description of Calreticulin (CALR1) mutation in 30-38% of 
non-Jak2/non-c-MPL mutated ETs. The del/ins mutation in the gene C-terminus or this intracellu-
lar protein chaperone and calcium controller is clinically associated with favorable prognosis if 
not occurring with other secondary hits, e.g. ASXL1 mutation.
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INTRODUCTION
In the spectrum of chronic myeloproliferative neoplasms (MPNs) only t(9;22)
(q34;q11) diagnostic for chronic myelogenous leukemia (CML) is specific for a sin-
gle disease. There is also a relative strong association for the del(13)(q12;q14) and 
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primary myelofibrosis (PMF), the rearrangements of PDGFRbR on 5q33 with vario-
us partner genes from 7q11, 10q21 and 17p13 are linked to chronic eosinophilia, as 
well as del(20)(q11;q13), +8, +9 is associated with polycythemia vera (PV). However, 
Essential thrombocythemia (ET) is the disorder for which no single recurrent chro-
mosomal abnormality has been described and only relatively unspecific structural 
and numerical karyotipic pathology is observed (see Table 1, Fig. 1).








del(13)(q12q14) PV, PMF AML, CLL, MM, MDS, NHL RB1 gene locus
del(20)(q11q13) PV, PMF, CNL AML, MDS 40 genes in the CDR
+8 all MPNs AML, ALL, MDS, LPD in ~10% cases
+9 PV, PMF AML, MDS ~ 2%
+21 PV, PMF AMl, ALL, MDS, t-AML, t-MDS ~ 3%
-7 PV, PMF, CMML, JMML ~ 8 %
-Y PV AML, ALL, LPD, MDS, MM, NHL ~ 15% male pts
JAK2V617F at 9p24 PV, PMF MDS, AML 40-55%
del(17)(p13) PMF, PV LPD, other hematopoietic npl. leukemic transformation 
+1q leukemic transformation
t(1;7)(q10;p10) - - leukemic transformation (ref. 4)
TPO gene - - herediatry thrombocythemia
c-MPLW515L/K ~ 1%
CALR1 del/ins 
mutation ET, PMF -
driver mutation
good prognosis
Abbreviations: PV, polycythaemia vera; PMF, primary myelofibrosis; CNL, 
chronic neutrophilic leukemia; MDS, myelodysplastic syndrome; AML, acute mye-
logenous leukemia, ALL, acute lymphoblastic leukemia; LPD, chronic lymphoproli-
ferative disease; MM, multiple myeloma; CDR, critical deleted chromosomal region; 
CLL, chronic lymphocytic leukemia; NHL, Non-hodgkin lymphoma; JMML, juve-
nile mylomonocytic leukemia.
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In the literature reported and summarized there have been approximately 400 
ET patients cytogenetically examined at diagnosis and some of them were later 
followed, some examined in the progression to acute leukemia [1-3]. Frequency of 
chromosomal anomalies was ranging from 5 to 7% at diagnosis and is the lowest 
among other MPNs. Generally, if found, observed chromosomal aberrations are sta-
ble in the course of the disease except for cases that transform and progress to acute 
leukemia where transformation can be associated with del(13)(q22) or appearance of 
translocations such are: t(2;17), t(3;17)(p24;q12), t(1;7)(q10;p10), t(6;11)(p24;q13) or chro-
mosome 1 long arm trisomy, monosomy 7q, del (17p): the site of TP53 gene (4,4,6). 
While initial karyotyping of ET seldom reveals pathology and is not included in the 
standard diagnostic criteria it is not considered mandatory in the first phase of the 
disease, but it may reveal clonal evolution when performed at the time of signs of 
hematological dynamics for individual patient in the course of the disease. 
Some of the apparent ET patients may harbor a masked Ph chromosome and 
this could lead to erroneous diagnosis of ET rather than CML. For this reason either 
molecular cytogenetics (FISH) of molecular test for bcr-abl fusion gene is recommen-
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Figure 1. Chromosomal map with depicted regions of numerical and structural aberra-
tions and loci of candidate genes for ET
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ded for the diagnostic workup of primary thrombocytosis. Thrombocytosis is also 
seen in some other myeloid malignancies, particularly myelodysplastic syndromes 
where del(5q-), t(3;3)(q21;q26) or inv(3)(q21;q26) can be expected. 8-15% of patients 
with the isolated interstitial deletion of the long arm of chromosome 5 and cha-
racteristic clinical features e.g. female sex, refractory anemia with mild leucopenia 
have also increased platelets, most likely due to haploinsufficiency of miR-145 and 
miRNA 146a expression from the remaining 5q allele.
The JAK2 V617F and CALR1 mutations in ET
The discovery of a recurrent, acquired point mutation G to T, with valine to phe-
nylalanine substitution at aminoacid 617 of the JAK2 (Janus Kinase 2) protein (JA-
K2V617F) leads to constitutive activation of the tyrosine kinase, increased kinase activity 
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Figure 2. Erythropoietin receptor (EPOR) and thrombopoietin receptor (MPL) signaling
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A and B: binding of ligand eg. erythropoietin or thrombopoietin to the receptor 
induces conformational changes resulting in phorphorylation (P) of JAK2 and the cyto-
plasmic tail of the receptor. In C: mutations either in JAK2 or cMPL lead to constitutive 
activation and increased signaling through pathways (JAK-STAT, PI3K, RAS-MAPK) 
even in the absence of the cytokine. CALR1 is a protein transporting chaperone from 
endocytoplasmic reticulum whose pathogenetic mechanism is not yet fully understood.
This mutation is present in most of the patients with PV and in around 50% of pati-
ents with PMF. The frequency of JAK2 mutation in ET patients published ranges from 
30% to 57% [7-9]. A substantial proportion of PV and PMF patients are homozygous for 
the mutant allele due to uniparental disomy resulting from mitotic recombination [9], 
but this phenomenon is rarely detected in ET [10]. The higher mutated allele burden 
increasing in the percentage from PV to PMF might reflect a biological continuum, 
where phenotypic presentation in part is influenced by mutated allele burden [11]. It 
is proposed that the low level of mutated JAK2 allele is sufficient for activation o MPL 
and that low level signaling is sufficient to induce thrombocytosis, but with the raise 
in the mutated alleles EPOR is activated with the induction of thrombocytosis asso-
ciated with polycythemia and even further activation is leading to polycythemia and 
finally very strong JAK V617F expression and signaling will be responsible for myelo-
fibrosis [12]. The JAK2V617F mutant allele burden in ET contributes to determining the 
clinical phenotype in patients with ET in terms of involvement of myeloid lineage pro-
liferation and higher risk or incidence of thrombosis or microvascular complications 
[13,14]. Patients with JAK2 mutation have multiple features resembling polycythemia 
vera, with significantly increased hemoglobin level and neutrophil counts, an incre-
ased risk of venous thrombosis and a higher rate of transformation to PV compared 
with patients without the mutation [13,15]. Furthermore, JAK2 V617F positive patients 
had lower serum ferritin and Epo concentrations, than did mutation-negative patients. 
Response to therapy also proved different in terms of having or not the mutation. 
JAK2 V617F-positive ET patients are more sensitive to therapy with hydroxyurea, but 
not anagrelide, compared with mutation-negative patients [13,16]. However, regarding 
the rate of thrombosis in ET patients according to JAK2 mutational status, discrepant 
results have also been reported stating that thrombotic events were similar between 
mutation-positive and mutation-negative patients [14]. Recently, a deletion/insertion 
mutation in calreticulin gene (CALR1) has been described in some 16-33% of ET and 
21-25% of MF leaving only approximately 10-15% of ETs and MFs without known mu-
tation. Two most frequent types of CALR1 mutations are deletion of 52bp and insertion 
of 5bp accounting for some 80% of all CALR1 mutations. Phenotypically CALR1 muta-
ted patients have higher platelet counts when compared to JAK2 mutated, have lower 
leukocytes and better prognosis in terms of EFS and OS [17,18].
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TPO and c-MPL mutations
Thrombopoietin (TPO) is the primary cytokine regulator of thrombopoiesis and 
it has been reported elevated in patients with ET compared to controls, but similar 
has been found in patients with other MPNs and in patients with reactive throm-
bocytosis, so measurement of TPO is not diagnostically useful. Mutations of the 
TPO gene were reported in some but not all kindreds with familial thrombocytosis, 
but they are not seen in sporadic ET [19,20]. The thrombopoietin receptor (c-MPL) is 
another candidate oncogene in ET. Reduced expression of c-MPL in platelets from 
patients with ET has been reported [21]. A highly penetrant gain-of-function MPL 
mutation in the transmembrane domain (MPLS505N) has been described for here-
ditary thrombocythemia [22]. Recently, an acquired mutation in c-MPL, MPLW515l, 
has been described that induces constitutive, cytokine-independent activation of the 
JAK-STAT pathway. Mutation is located in the sequence important for keeping the 
receptor inactive [23]. (Fig2). Furthermore, the expression of MPLW515L in murine 
bone marrow resulted in an MPD phenotype. MPLW515l or MPLW515K mutations 
are present in patients with PMF or ET at a frequency of approximately 5% and 1%, 
respectively, but are not observed in patients with polycythemia vera (PV) or other 
myeloid disorders. MPL mutations may occur concurrently with the JAK2V617F mu-
tation, suggesting that these alleles may have functional complementation in mye-
loproliferative disease [24]. 
Other molecular markers in ET
By using microarray technology to study the malignant megakaryocytopoiesis 
of ET the expression of genes involved in the apoptotic pathway was found impaired 
in ET CD34-derived megakaryocytes (MK). Moreover, CD34-derived MKs of patients 
with ET were more resistant to apoptosis than their normal counterparts. Proapopto-
tic genes BAX, BNIP3, and BNIP3L were down-regulated in ET MKs together with ge-
nes that are components of the mitochondrial permeability transition pore complex, a 
system with a pivotal role in apoptosis. Conversely, antiapoptotic genes such as IGF1-
R and CFLAR were up-regulated in the malignant cells, as was the SDF1 gene, which 
favors cell survival [25]. Overexpression of polycythemia rubra vera-1 (PRV-1) gene 
was found in PV, PMF and ET. Overexpression of PRV-1 may be associated with a su-
bset of patients who may be initially defined as ET by diagnostic criteria but may later 
evolve in PV [14,27]. Another potential candidate molecule able to distinguish betwe-
en frequently overlapping phenotypes or PV and ET is the expression of angiotensin 
receptor II (AT2R1) that is highly expressed on hematopoietic cells in PV but not in ET 
and this irrespective of the JAK2 mutational status of ET [28].
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Sažetak
Genetički aspekti mijeloproliferativnih neoplazmi
Esencijalna trombocitemija je jedna od tri Filadelfija–kromosom-negativne kronične mijelo-
proliferativne neoplazme (MPN). Drži se za relativno benignog tijeka s preživljenjem pacijenata 
sličnom onom opće populacije, Ipak, kao klonalna bolest matične stanice može napredovati u 
sekundarnu fibrozu ili transformirati u akutnu leukemiju. Pokazuje povišeni rizik za hemoragiju 
( osobito ako su brojevi Tr viši od milijun u mikrolitru) ili trombozu. U posljednjih 10-tak godina 
postignut je veliki napredak u razumijevanju genetičke osnove ove bolesti. Najvažnija su otkriće 
točkaste mutacije V617F gena Janus kinaza 2 (JAK2V617F) koja postoji u 90-tak % ET, > 97% PV 
te 50% MF. Mutacija trombopoetinskog receptora je također važna pri čemu W515L mutacija 
potiče konstitucijsku aktivnost, nezavisnu od citokina za aktivaciju JAK-STAT signalnog puta. 
MPLW515L ili MPLW515K su prisutne u otprilike 3% slučajeva. Nedavno je otkrivena mutacija 
gena za protein endocitoplazmatskog retikuluma, kalretikulina 1 (CALR1). Riječ je o ins/del mu-
taciji koja je prisutna u 30-38% ET i 21-25% MF, JAK2/MPL-mutacija negativnih. Klinički je ova 
mutacija povezana s povoljnom prognozom, u koliko nema dodatnih mutacija poput ASXL1, a 
koja onda donosi nepovoljan prognostički trend.
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